Early Cystic Fibrosis Lung Disease Studies in Humans, NHLBI (R01)

Post Date

August 19th 2011

Application Due Date

January 11th 2012

Funding Opportunity Number

RFA-HL-12-035

CFDA Number(s)

93.838

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $3000000

• Award Range:

  $None - $400000

Grant Description

This FOA, issued by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, invites Research Project Grant (R01) applications that propose to investigate the early origins of cystic fibrosis (CF) lung disease and the mechanisms involved in development and progression of pulmonary abnormalities in young children with this condition. Studies may explore novel strategies for detecting early lung disease in infants and young children with CF, including minimally invasive biomarkers and/or imaging approaches, and utilize these methods to elucidate the molecular and cellular mechanisms of early lung disease onset and progression. The ultimate goal is development of novel approaches for diagnosis, prevention, and treatment of early CF lung disease.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-035.html